Summary of Envista Holdings Corporation Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: $731 million, with a 5% core growth year-over-year.

Adjusted EBITDA: Increased by 28% to $107 million, with an adjusted EBITDA margin of 14.7%, up 230 basis points.

Earnings Per Share (EPS): Adjusted EPS rose 58% to $0.41.

Free Cash Flow: $105 million, representing a 158% conversion rate of adjusted net income.

Gross Margin: 55.1%, an increase of 70 basis points from the prior year.

2Strategic Updates and Business Highlights

Core Growth: Strong performance across all segments and geographies, with Equipment & Consumables (E&C) growing 8.5% and Specialty Products & Technologies (SP&T) growing over 3%.

Product Innovation: Launched new products in consumables and orthodontics, including ZenSeal Pro and DemiPro, contributing to market share gains.

Operational Excellence: Continued benefits from the Envista Business System, leading to improved manufacturing productivity and gross margin expansion.

Share Buyback: Repurchased 2.4 million shares at an average price of $24 per share.

3Forward Guidance and Outlook

Updated Full-Year Guidance:

Core growth expected to be 3.5% to 4.5%.

Adjusted EBITDA growth projected at 11% to 14%.

Adjusted EPS forecasted between $1.50 and $1.55.

Second Half Expectations: Anticipated slower revenue growth due to a calendar effect (4 fewer selling days in Q4) and the impact of upcoming Value-Based Pricing (VBP) adjustments in China.

4Bad News, Challenges, or Points of Concern

China VBP Impact: Anticipated price declines of 10-15% for implants and similar pressures for ortho, potentially affecting margins and volume growth.

Market Conditions: The North American market is currently softer, which could impact future growth, particularly in more elective categories like implants.

Billing Day Effect: Expected to negatively impact Q4 revenue growth, making it flat to slightly down.

Competitive Pressures: Ongoing need to navigate macroeconomic uncertainties and competitive dynamics in the dental market.

5Notable Q&A Insights

E&C Segment Growth: Driven by market resilience and share gains, particularly in consumables and diagnostics, which are less sensitive to macroeconomic pressures.

VBP Dynamics: The upcoming VBP processes are expected to provide market share gains despite price reductions, with implications for both ortho and implants.

Investment in R&D: Continued focus on innovation and product development is seen as crucial for maintaining competitive advantage.

M&A Strategy: Emphasis on strategic, financially accretive acquisitions to enhance growth in the implant sector. Overall, Envista reported strong financial results for Q2 2026, driven by broad-based growth and operational improvements, while also navigating potential challenges from pricing pressures in China and macroeconomic uncertainties. The company remains optimistic about its strategic initiatives and future growth prospects.